Page 42 - MBCA_FULL REPORT_FINAL_FOR_WEB

Trials from the Translational Breast Cancer Research Consortium
In addition to reviewing actively recruiting trials from the NCI PDQ database, we reviewed
both ongoing and completed clinical trials from the Translational Breast Cancer Research
Consortium (TBCRC) that were related to MBC [14] . The TBCRC was founded in 2005 and has
been funded, in part, by Alliance members: Breast Cancer Research Foundation, Susan G.
Komen, and the Avon Foundation. The TBCRC is a collaborative, multi-institution, academic
group that conducts innovative and high-impact clinical trials for breast cancer. The TBCRC is
composed of 17 clinical sites, 5 core subcommittees, and working groups. Collectively, these
groups work together to foster trial development and enrollment in a collegial environment that
enhances cross-institutional collaborations. The activity of the TBCRC is of interest because it
is an exemplary model of collaboration, accelerating clinical research related to breast cancer
and MBC. The collaboration includes 19 leading academic medical centers and principal
investigators launching joint trials, recruiting patients together, and sharing valuable tissue
sources and samples.

Upon analysis, we found that, of the 30 multicenter clinical trials conducted since the inception
of the TBCRC in 2005, 15 (50%) either targeted or included MBC patients (see Table 4). Of
these 15 trials, 12 were either not yet fully active or closed to accrual. Because our dataset only
includes trials that were active or recruiting patients in April and May 2014, these 12 trials are not
included, although the 3 active TBCRC trials are included. Across all 15 MBC trials from TBCRC,
17 new drugs or combinations of drugs have been or are being tested.

42